READ THE LATEST
Your Front-Row Seat to the Future of Lung Cancer Care
The International Lung Cancer Survivorship Conference (ILCSC) is almost here—September 26-27, 2025! Explore the full agenda of expert-led sessions and see what’s ahead:
AI in Cancer Care: What’s hype and what’s truly transformative?
Targeted Therapies & Immunotherapy: Where research breakthroughs are leading us next
Managing Survivorship: Practical strategies for navigating side effects, wellness, and long-term care
Whether you're newly diagnosed or years into survivorship, ILCSC offers education, support, and empowerment—all from home. Register for free today.
Breathe Deep TOGETHER: A National Day of Action for Lung Health
On Saturday, November 8, 2025, join us in Boston, DC, or NYC—or from your own neighborhood—for Breathe Deep TOGETHER. This powerful and inspiring day features the Lung Health Resource Fair, family-friendly activities, and community walks, all designed to honor loved ones and rally for change.
Your fundraising fuels research and support programs that directly impact patients, survivors, and families. Every dollar matters.
Let’s come together to make lung cancer a national priority.
Every Flag Tells a Story: A Tribute on the National Mall
This November, LUNGevity will cover the National Mall in Washington, DC, with 60,000 white flags, each representing two lives lost to lung cancer this year—a powerful reminder of the urgency of action needed. Behind every flag is a story, a family, a life that fuels our mission to drive change.
Be part of this historic installation. Volunteer today to help place flags and share the stories that make this tribute so powerful.
Walk among the flags. Honor loved ones. Lend your hands and heart. Sign up to volunteer today.
Looking for a clinical trial?
Check out our vetted list of currently enrolling trials — and make sure to check regularly for new trials as they are added.
Collaborating for Change: Lung Cancer Advocacy Webinar Series
On August 20, LUNGevity co-hosted the second Policy and Advocacy Update for the Lung Cancer Community webinar in partnership with GO2 for Lung Cancer, the American Lung Association, and the American Cancer Society Cancer Action Network (ACS CAN). Policy staff from each organization spoke about the current status of research funding and key health agencies, as well as the implications of the recent budget reconciliation bill. If you missed the webinar or would like to watch it again, the recording is available here.
Join Us for the 2025 Chi Town Turkey Trot!
VOLUNTEERS NEEDED!
Thursday, November 27 (Thanksgiving Day), 7:15–11:00 am
DuSable Harbor, 111 N Lake Shore Dr., Chicago
LUNGevity is partnering with the 2025 Chi Town Turkey Trot 5K & 10K as the official charity, and we need your help!
We are looking for at least 30 enthusiastic volunteers to help make race day a success. Whether you're helping with registration, managing water stations and post-race food tents, or handing out medals, there’s a role for everyone! All volunteers will receive a free event t-shirt and safety vest as a thank-you for your time and support.
Make it a family affair! The minimum age to volunteer alone is 15, but those under 15 can still volunteer with adult supervision.
LUNGevity's Conversations that Count speaker series gives you a seat at the table as top experts engage in critical discussions.
Next Tuesday we welcome Derrick Butts, board president and co-founder of Prostate Health Matters, to talk about best practices for engaging patients and community members in prostate cancer education and how we can apply those learnings to the lung cancer community.
Small Cell SMASHERS Fireside Chat
TUESDAY, SEPT. 30 | 1-2 PM ET
Each month, the Small Cell SMASHERS Fireside Chats highlight the latest discoveries, topics, and tips for living well with SCLC. Hosted by Misty Shields, MD, PhD, IU Health, and LUNGevity's Ann Fish-Steagall, RN, BSN, they welcome a new expert each month to share information and answer audience questions.
Join us for the next Fireside Chat on Tuesday, September 30, to learn about the importance of real-world data for treating small cell lung cancer with Sonam Puri, MD, Department of Thoracic Oncology at H. Lee Moffitt Cancer Center.
Make sure to follow us on Facebook and join the Fireside Chat live.
FDA Approves First Oral Therapy for Advanced HER2+ NSCLC
On August 8, the US Food and Drug Administration (FDA) granted accelerated approval to zongertinib, the first oral targeted therapy for advanced non-small cell lung cancer (NSCLC) with HER2 mutations. These mutations, found in about 2–3% of nonsquamous NSCLCs, are known to drive tumor growth. Learn more about this new treatment option.
RESEARCH CORNER
Research drives progress—and saves lives.
As new questions emerge about lung cancer, researchers rise to meet them—uncovering the biology behind the disease and developing critical therapies that offer patients more time and better outcomes. Their discoveries are transforming what it means to live with lung cancer.
But the work is far from over. Continued research, with the support of the lung cancer community, is essential to ensure that every patient has access to better options and new hope.
Why Do People Without Significant Tobacco Exposure Get Lung Cancer?
As tobacco use has declined in recent years, we have seen a new demographic of patients with lung cancer emerge. Lung cancer in individuals without tobacco exposure (also called lung cancer in never-smokers or LCINS) is becoming more common.
Researchers have uncovered some potential risk factors such as genetics and environmental exposure. In addition, they are exploring methods for early detection and targeted treatment.
Learn more about this important research with Jaclyn LoPiccolo, MD, PhD, of the Dana-Farber Cancer Institute.
LUNGevity Research at WCLC 2025
Earlier this week, LUNGevity’s patient-focused lung cancer studies were featured at the World Conference on Lung Cancer (WCLC) in Barcelona, Spain, the largest international gathering of lung cancer experts, and highlight and address key areas of need in the lung cancer space.
Here are the topics we presented:
Evidence Synthesis of Non-Screen-Eligible Cohorts and Implications for Lung Cancer Advocacy: This research study identified key opportunities to expand eligibility for lung cancer screening to reach up to 5 million more people.
Assessing the Impact of Project ASCENT, a Multi-Level Lung Cancer Screening Intervention Targeting Hispanic/Latin Individuals: In partnership with the Miami Cancer Institute, this study created a culturally relevant screening program for Hispanic/Latin communities to increase lung cancer screening uptake and tobacco cessation referrals.
Giving Back – Co-creation of Data Dashboard to Share Online Survey Results: In partnership with the EGFR Resisters patient group, this project developed and launched the EGFR Data Explorer, a free online platform to share aggregated patient experience data directly with patients and caregivers to empower decision-making.
Treatment Changes over 12 Months of Observation for ALK- and EGFR-Positive NSCLC - Results from a Real-World Study: This research highlights how patients with ALK+ or EGFR+ stage IV lung cancer experience treatment changes in real life and underscores the need to look beyond clinical trials to improve patient outcomes.
Together, these studies underscore LUNGevity’s commitment to research that not only expands the frontiers of science through our grants programs but also builds opportunities for equity and advocacy to improve the patient experience through patient-focused research.
Interested in learning more about research presented at this year’s WCLC? Our team is returning from Spain and bringing the biggest research highlights with them. Keep an eye out for LUNGevity’s expert coverage of the news and breakthroughs discussed at the conference.
LUNGevity is transforming what it means to be diagnosed and live with lung cancer.
Support our mission by making a tax-deductible donation today.
